<DOC>
	<DOCNO>NCT01511536</DOCNO>
	<brief_summary>Primary Objectives : - To determine maximum tolerate dose , dose limit toxicity cabazitaxel administer 1-hour infusion every 3 week combination oral daily abiraterone acetate prednisone participant metastatic Castrate-resistant prostate cancer ( CRPC ) - To estimate anti-tumor activity cabazitaxel combination abiraterone acetate prednisone term prostate-specific antigen ( PSA ) response rate . Secondary Objectives : - To characterize safety profile combination - To evaluate pharmacokinetic profile cabazitaxel abiraterone propose combination dose schedule - To assess preliminary antitumor activity combination term progression-free survival , PSA progression free survival objective response rate , overall survival</brief_summary>
	<brief_title>Cabazitaxel Abiraterone Acetate Patients With Metastatic Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>The study duration include period inclusion 3 week 3-week treatment cycle ( ) . The participant might continue treatment disease progression , unacceptable toxicity willingness stop follow minimum 30-day follow-up</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Inclusion criterion : Diagnosis prostate adenocarcinoma prove histologically cytologically , resistant hormone therapy previously treat docetaxelcontaining regimen . In Phase 2 part , participant treat abiraterone acetate least 3 month continue treatment abiraterone acetate study entry Presence metastatic prostate cancer . Participant must progressive disease document rise PSA define 2 sequential increase previous low reference value ( PSA value must obtain least 1 week apart . A PSA value least 6 ng/mL require study entry ) . In Phase 1 part , addition rise PSA , progressive disease must document : 1 . Increase nonmeasureable measurable disease , and/or 2 . Appearance new lesion , include bone scan ( ≥2 new lesion 2 consecutive bone scan progressive disease diagnose bone scan ) consistent progressive prostate cancer Effective castration ( serum testosterone level ≤0.50 ng/mL ) orchiectomy and/or luteinizing hormonereleasing hormone agonist /antagonist . 1 . If participant treat luteinizing hormonereleasing hormone agonists/antagonist ( i.e. , without orchiectomy ) , therapy initiate least 4 week prior cycle 1 day 1 continue throughout study . 2 . Prior antiandrogen therapy stop enrollment Eastern Cooperative Oncology Group performance status : 0 1 . Exclusion criterion : Previous treatment mitoxantrone cabazitaxel . Prior boneseeking radioisotope therapy ( participant treat Radium223 exclude study ) . Radiotherapy ≥30 % bone marrow . Adverse event prior anticancer therapy grade &gt; 1 time enrollment . Prior surgery , radiation , chemotherapy , anticancer therapy within 4 week prior enrollment study ( except luteinizing hormonereleasing hormone agonist /antagonist abiraterone acetate Phase 2 part study ) ; small field single fraction palliative radiation within 1 week . Prior malignancy . Curatively treated basal cell squamous cell skin superficial ( pTis , pTa , pT1 ) bladder cancer allow , well cancer chemotherapy complete ≥ 3 year ago participant diseasefree ≥ 3 year . Participation another clinical trial concurrent treatment investigational drug within 30 day prior enrollment . Known brain leptomeningeal metastasis . Any severe acute chronic medical condition could impair ability participant participate study comply study procedure interfere interpretation study result . Other concurrent serious illness medical condition Absence sign date participant inform consent form prior enrollment study . History hypersensitivity docetaxel , polysorbate 80 Known allergy , hypersensitivity intolerance prednisone excipients abiraterone acetate Known history mineralocorticoid excess deficiency Inadequate organ bone marrow function Contraindications use corticosteroid treatment . Symptomatic peripheral neuropathy grade &gt; 1 Concurrent treatment strong inducer strong inhibitor cytochrome P450 ( CYP450 ) 3A4 Concurrent treatment medication metabolize cytochrome P2D6 ( CYP2D6 ) , particularly small therapeutic window History cardiac arrhythmia require medical therapy atrial fibrillation require anticoagulation digoxin/digitalis ; uncontrolled angina pectoris . History congestive heart failure myocardial infarction within last 6 month also allow . Uncontrolled hypertension ( systolic BP ≥160 mmHg diastolic BP ≥ 95 mmHg ) . Participants history hypertension allow , provide blood pressure control within limit antihypertensive treatment Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 12 month , severe unstable angina , New York Heart Association Class III IV heart disease cardiac leave ventricular ejection fraction measurement &lt; 50 % baseline Participants reproductive potential agree use accept effective method contraception conjunction partner ( ) study treatment period . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>